Physician profile
Regina M Wright
NPI 1043216872
$1,072.62
in general payments reported to CMS, 2019-2025
23 companies · $16.71 in 2025
The $16.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $121 · 2021: $166 · 2022: $332 · 2023: $114 · 2024: $193 · 2025: $16.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.45 | 2020-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.15 | 2019-2022 | |
| Abbott Laboratories | $90.76 | 2019-2023 | Jot Dx, Prodigy |
| Boston Scientific Corporation | $75.90 | 2019-2022 | |
| Hologic Sales and Service, LLC | $51.66 | 2020-2024 | Aptima |
| Glaxosmithkline, LLC. | $47.52 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $43.07 | 2020-2024 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $42.38 | 2020-2021 | |
| Amgen INC. | $38.36 | 2022-2025 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $37.42 | 2021-2024 | Fasenra |
| Biotronik INC. | $35.39 | 2021-2022 | |
| Dexcom, INC. | $32.13 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $27.01 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Vanda Pharmaceuticals INC. | $20.45 | 2022 | |
| Axonics, INC. | $20.21 | 2023 | Axonics |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $19.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.72 | 2019 | |
| Inspire Medical Systems, INC. | $17.02 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $14.89 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.67 | 2024 | Quviviq |
| Medtronic Vascular, INC. | $14.37 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.64 | 2021 | |
| Therapeuticsmd, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.